Richard Gorlick, MD (MD Anderson Cancer Center)
Michael Roth, MD (Children’s Hospital at Montefiore)
David Loeb, MD, Ph.D. (Johns Hopkins University)
Nicolas Llosa, MD (Johns Hopkins University)
Brian Ladle, MD, PhD (Johns Hopkins University)
Ian Davis, MD, Ph.D. (University of North Carolina at Chapel Hill)
Patrick Thompson, MD (University of North Carolina at Chapel Hill)
This study explores the ways in which certain drugs, epigenetic modifiers, change the immune system and cancer. We plan to leverage the results of this unique, 3 institution collaboration towards the development of future Sunshine Project clinical trials such as an emerging concept for assessing the therapeutic utility of checkpoint inhibitors in combination with 5-azacitidine in patients with osteosarcoma.
Osteosarcoma outcomes have not significantly improved over the past three decades. This preclinical proposal has clear translational benefits. By defining the biology and efficacy of combined therapy with an anti-PD-1 antibody and 5-azacytidine, researchers hope to establish the basis for developing this approach into a potential Sunshine Project clinical trial for children with relapsed or refractory osteosarcoma.
https://nationalpcf.org/wp-content/uploads/2018/08/CGI-image-of-a-magnifying-glass-looking-at-a-cancerous-cell.jpg6301500Jared Bennetthttps://nationalpcf.org/wp-content/uploads/2019/05/National-Pediatric-Cancer-Foundation-Logo.pngJared Bennett2018-08-07 16:23:362018-08-13 13:46:52Preclinical Study of Anti-PD-1 Antibody in Combination with 5-Azacytidine in Mouse Models of Osteosarcoma
National Pediatric Cancer Foundation (NPCF) is a nonprofit organization dedicated to funding research to eliminate childhood cancer.
Top Rated Charity
The National Pediatric Cancer Foundation has received a perfect 100% score for financial health and transparency and is the top-rated childhood cancer charity in the United States by Charity Navigator.